JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

JNJ

225.99

+0.78%↑

UNH

363.44

-1.74%↓

TMO

468.75

+1.08%↑

ISRG

451.32

+0.19%↑

ABT

87.64

+0.15%↑

Kodu・Aktsiate loetelu・Heron Therapeutics Inc
Search

Heron Therapeutics Inc

Suletud

SektorTervishoid

1.22

Osta

Hinna uuendus 5. mai 2026, 19:57 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.19

Max

1.22

Põhinäitajad

By Trading Economics

Sissetulek

15M

-3M

Müük

2.4M

41M

Aktsiakasum

-0.02

Kasumimarginaal

-7.278

Töötajad

128

EBITDA

13M

-792K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+268.85% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. mai 2026

Turustatistika

By TradingEconomics

Turukapital

6.2M

224M

Eelmine avamishind

1.22

Eelmine sulgemishind

1.22

Uudiste sentiment

By Acuity

7%

93%

5 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

2.0001 / 2.42 Toetus ja vastupanu

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

4. mai 2026, 22:17 UTC

Tulu

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Loe

4. mai 2026, 23:47 UTC

Tulu

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Loe

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Loe

4. mai 2026, 23:45 UTC

Tulu

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Loe

4. mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Loe

4. mai 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Loe

4. mai 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Loe

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Loe

4. mai 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Loe

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Loe

4. mai 2026, 22:41 UTC

Omandamised, ülevõtmised, äriostud

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Shareholders to Own About 51% of Combined Company

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Loe

4. mai 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Regis: Deal Unanimously Recommended by Vault Board

DJ

Loe

4. mai 2026, 22:39 UTC

Omandamised, ülevõtmised, äriostud

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Loe

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Loe

4. mai 2026, 22:38 UTC

Omandamised, ülevõtmised, äriostud

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Loe

4. mai 2026, 22:37 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Loe

4. mai 2026, 22:26 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Loe

4. mai 2026, 22:02 UTC

Tulu

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Loe

4. mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Loe

4. mai 2026, 21:52 UTC

Tulu

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Loe

4. mai 2026, 21:50 UTC

Tulu

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Loe

4. mai 2026, 21:50 UTC

Tulu

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Loe

4. mai 2026, 21:49 UTC

Tulu

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Loe

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Loe

4. mai 2026, 21:44 UTC

Tulu

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Loe

4. mai 2026, 21:43 UTC

Tulu

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Loe

4. mai 2026, 21:41 UTC

Tulu

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Loe

4. mai 2026, 21:40 UTC

Tulu

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

268.85% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD  268.85%

Kõrge 6 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Põhineb 2 analüütiku instrumendi Heron Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.0001 / 2.42Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Bullish Evidence

Recent bullish events outweigh bearish events.

Pikk perspektiiv

Bullish Evidence

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

5 / 347 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Muud aktsiad sektorist

JNJ

Johnson and Johnson

225.99

↑ +0.78%

UNH

UnitedHealth Group Inc

363.44

↓-1.74%

TMO

Thermo Fisher Scientific Inc

468.75

↑ +1.08%

ISRG

Intuitive Surgical Inc

451.32

↑ +0.19%

ABT

Abbott Laboratories

87.64

↑ +0.15%
help-icon Live chat